GSK posts late-stage trial win for co-administered RSV and shingles ...
WEB8m. G SK (NYSE: GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were ...
GSK Announces Positive Topline Data on Co-Administration
WEB2 days ago · Shingles is caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox. 11 By age 50, VZV is present in most adults 12 and may reactivate with advancing ...
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles …
WEB1 day ago · Wednesday, GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial ...
GSK's RSV vaccine meets main goal when co-administered with shingles …
WEB2 days ago · British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years ...
New long-term data show SHINGRIX continues to provide high ... - GSK
WEBApr 17, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with SHINGRIX (Recombinant Zoster Vaccine or RZV).
New data show Shingrix can provide at least 10 years of ... - GSK
WEBOct 19, 2022 · The Recombinant Zoster Vaccine (RZV) is the first approved shingles vaccine to combine a non-live antigen with GSK’s adjuvant and may help overcome the natural age-related decline in immunity that contributes to the challenge of protecting adults aged 50 years and above from this disease.
New Shingrix data demonstrate 100% vaccine efficacy in the ... - GSK
WEBAug 23, 2023 · GSK plc (LSE/NYSE: GSK) today announced positive results from the first-ever efficacy trial of Shingrix (Recombinant Zoster Vaccine or RZV) in China. These results come from the post-license phase IV trial (ZOSTER-076), which evaluated the efficacy and safety of RZV in preventing shingles in adults aged 50 and over.
Shingrix approved in the US for prevention of shingles in adults ... - GSK
WEBGlaxoSmithKline plc [LSE/NYSE: GSK] today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 50 years and older.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
WEB2 days ago · Resize. By Robb M. Stewart. GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and ...
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
WEB1 day ago · GSK on Wednesday unveiled promising topline Phase III data for a combo regimen of its RSV vaccine Arexvy and shingles shot Shingrix, touting a comparable immunogenicity profile to the individual vaccines. The company did not provide specific data in its announcement, only noting that co-administering …